'Selective' COX-1 or COX-2 NSAIDs: time to change a misleading measure

J Clin Pharm Ther. 2014 Oct;39(5):455-6. doi: 10.1111/jcpt.12192. Epub 2014 Jul 29.

Abstract

The ongoing important debate about the relative benefits/risks of COX-1 or COX-2 NSAIDs is hampered by the use of a measure of 'selectivity' that is inherently flawed. An alternative measure provides more meaningful and clinically relevant information.

Publication types

  • Editorial

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics*
  • Confounding Factors, Epidemiologic
  • Cyclooxygenase 1 / metabolism
  • Cyclooxygenase 2 Inhibitors / metabolism
  • Cyclooxygenase Inhibitors / metabolism
  • Humans
  • Inhibitory Concentration 50

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Cyclooxygenase 1